POZEN Inc. : POZEN’s Digital Advisory Board to Speak at Annual ePharma Summit
02/02/2012 | 08:36am
Board to Describe How Pharma Can Look Beyond Healthcare for
Best Practices in Digital Communications
NEW YORK--(BUSINESS WIRE)--Feb. 2, 2012-- POZEN Inc. (NASDAQ:
POZN),a pharmaceutical company committed to transforming
medicine that transforms lives, announced today that its
Digital Advisory Board, an esteemed group of digital
thought-leaders both in and outside of healthcare, is
participating in the eleventh annual ePharma Summit, a
conference showcasing healthcare industry experts' views on
the evolution of digital marketing and how to reach consumers
and physicians through social and digital media. A
POZEN-sponsored panel discussion titled, "Transforming the
Pharma Industry - Breakthrough Perspectives from Digital
Leaders," will be held on Tuesday, February 7, 2012 from
10:50 - 11:25 a.m. at the Sheraton New York Hotel & Towers.
"POZEN and its Digital Advisory Board are excited to be among
the distinguished attendees speaking at this prominent
digital marketing event," said Liz Cermak, Executive Vice
President and Chief Commercial Officer, POZEN Inc., and
moderator of the discussion. "Comprised of some of the most
influential voices and thought-leaders in the digital and
social media space, our board will share their diverse
perspectives and experiences and offer valuable insight into
how pharmaceutical companies can leverage new digital
strategies to more effectively engage physician and patient
audiences."
During the session, the Digital Advisory Board members will
share their experiences, offering their perspectives on how
to evolve traditional pharmaceutical marketing to best meet
the needs of target audiences. The Digital Advisory Board has
been working alongside POZEN as it prepares for the launch
and marketing of its lead compound PA32540, which is being
investigated for the secondary prevention of cardiovascular
disease in patients at risk for aspirin-induced gastric
ulcers. They have helped POZEN design the actual Launch Plan
for the brand.
About the Digital Advisory Board
POZEN, a progressive, specialty pharmaceutical company,
formed the Digital Advisory Board to help advance the
Company's vision of creating a new pharma commercial model.
POZEN's Digital Advisory Board members include:
-
Raj Amin, Chief Executive Officer and Co-Founder,
HealthiNation
-
Bonin Bough, Senior Director of Digital and Social Media,
PepsiCo
-
Marc Monseau, Founder and Principal, MDM Communications
-
Daniel Palestrant, MD, Chief Executive Officer and Founder,
Par8o, former SERMO Founder
-
Meredith Ressi, President, Manhattan Research
POZEN's goal in collaborating with these Advisors is to look
beyond the pharmaceutical industry to leverage best practices
as well as identify untapped digital strategies that will
help shape plans to deliver affordable, accessible medicines
to customers.
About POZEN
POZEN Inc. is a progressive pharmaceutical company that is
transforming how the healthcare industry addresses unmet
medical needs. By utilizing a unique in-source model and
focusing on integrated therapies, POZEN has successfully
developed and obtained FDA approval of two self-invented
products in two years. Funded by these two milestone/royalty
streams, POZEN is now creating a portfolio of cost-effective,
evidence based integrated aspirin therapies designed to
enable the full power of aspirin by reducing its GI damage.
POZEN is currently seeking strategic partners to help
maximize the opportunity for its portfolio assets.
The Company's common stock is traded under the symbol
"POZN" on The NASDAQ Global Market. For more detailed company
information, including copies of this and other press
releases, please visit
www.pozen.com.
About PA
POZEN is creating a portfolio of integrated aspirin therapies
- the PA product platform. The products in the PA portfolio
are intended to significantly reduce GI ulcers and other GI
complications compared to taking aspirin alone.
The first candidate is PA32540. It is a coordinated-delivery
tablet combining immediate-release omeprazole, a proton pump
inhibitor, layered around pH-sensitive aspirin. This novel,
patented product is administered orally once a day and will
be indicated for use for the secondary prevention of
cardiovascular disease in patients at risk for
aspirin-induced ulcers. POZEN has completed enrollment for
the long-term safety study and the two pivotal studies,
targeting a New Drug Application filing in 3Q12.
Forward-Looking Statements
Statements included in this press release that are not
historical in nature are "forward-looking statements" within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995.You should be aware
that our actual results could differ materially from those
contained in the forward-looking statements, which are based
on current market data and research (including third party
and POZEN sponsored market studies and reports), management's
current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and
delays in the development and/or FDA approval of our product
candidates, including as a result of the need to conduct
additional studies, or the failure to obtain such approval of
our product candidates, including as a result of changes in
regulatory standards or the regulatory environment during the
development period of any of our product candidates;
uncertainties in clinical trial results or the timing of such
trials, resulting in, among other things, an extension in the
period over which we recognize deferred revenue or our
failure to achieve milestones that would have provided us
with revenue; our inability to maintain or enter into, and
the risks resulting from our dependence upon, collaboration
or contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and
distribution of any products, including our dependence on
GlaxoSmithKline for the sales and marketing of Treximet® and
our dependence on AstraZeneca for the sales and marketing of
VIMOVO™; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to
third party patents and intellectual property to operate our
business; our inability to operate our business without
infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to
gain market acceptance; our inability to obtain any
additional required financing; technological changes;
government regulation; changes in industry practice; and
one-time events, including those discussed herein and in our
Quarterly Report on Form 10-Q for the period ended September
30, 2011. We do not intend to update any of these factors or
to publicly announce the results of any revisions to these
forward-looking statements.
Source: POZEN Inc.
POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer
or
Stephanie Bonestell, 919-913-1030
Manager, Investor Relations & Public Relations
